A pós-menopausa é marcada por alterações fisiológicas hemodinâmicas e metabólicas. A terapia de reposição estrogênica é uma forma de amenizar as conseqüências da deficiência hormonal e o exercício físico contribui significativamente para a redução do risco cardiovascular. O objetivo desse estudo foi avaliar em mulheres pós-menopausadas os efeitos isolados e associados da terapia oral estrogênica (TRH) e do treinamento físico aeróbio (TF) nas respostas hemodinâmicas e neurais basais e durante os exercícios com handgrip. Quarenta e cinco mulheres (51±3 anos), histerectomizadas, com e sem ovários, saudáveis, realizaram uma sessão experimental e, posteriormente foram divididas em 4 grupos SED-PLA (n=11), SED-TRH (n=14), TF-PLA (n=12) e TF-TRH (n=8). Os grupos TRH e receberam valerato de estradiol 1mg/dia; PLA receberam placebo; TF, realizaram exercício aeróbio em cicloergômetro por 50 minutos, 3 vezes por semana e SED permaneceram sedentárias. Todas as voluntárias participaram de uma segunda sessão experimental após 6 meses de acompanhamento. Nas sessões experimentais foram avaliadas a atividade nervosa simpática periférica (ANSP - microneurografia), pressão arterial, freqüência cardíaca (FC - método oscilométrico Dixtal no membro inferior), fluxo sangüíneo do antebraço (FSA - pletismografia) em um período basal e durante exercícios estático e dinâmico com handgrip a 30% da força de contração máxima. Para análise estatística foi utilizada ANOVA. O TF isoladamente diminuiu ANSP de 40±7 a 34±4 impulsos/min, (P=0,01) e aumentou FSA de 1,92±0,96 a 2,65±1,34 ml(min.100ml), P=0,03 no período basal. TRH e TF associados reduziram a FC no período basal de 65±8 para 62±7 bpm (P=0,01) e durante o exercício estático e dinâmico com handgrip. A TRH de maneira isolada ou associada ao TF diminuiu as respostas de FC durante os exercícios estático e dinâmico com handgrip. Em conclusão, as intervenções de maneira isolada ou associada promovem alterações hemodinâmicas e neurais que podem contribuir para redução do risco cardiovascular de mulheres pós-menopausadas saudáveis. / The post-menopause is marked by physiological hemodynamic and metabolic changes. The estrogen replacement therapy is a way to reduce the consequences of hormone deficiency and physical exercise contributes significantly to the reduction of cardiovascular risk. The aim of this study was to evaluate in post-menopausal women the isolated and associated effects of oral estrogen therapy (TRH) and physical training (TF) in the neural and hemodynamic responses during baseline and \"handgrip\" exercises. Forty-five women (51 ± 3 years), hysterectomized, with or without ovaries, healthy, participated of an initial session and then they were divided into 4 groups SEDPLA (n = 11), SED-TRH (n = 14), TF-PLA (n = 12) and TF-TRH (n = 8). The TRH groups received estradiol valerate 1 mg / day; PLA placebo; TF, performed aerobic exercise on a cycle ergometer for 50 minutes, 3 times a week and SED remained sedentary. All subjects participated in a second experimental session after 6 months of follow-up. In the experimental sessions peripheral sympathetic nerve activity (ANSP - microneurography), blood pressure, heart rate (FC - oscillometry - Dixtal lower limb), forearm blood flow (FSA - plethysmography) were evaluated at the baseline period and during static and dynamic \"handgrip\" exercises at 30% of the maximum force. ANOVA was used for the statistica analysis. The TF alone decreased ANSP from 40 ± 7 to 34 ± 4 bursts/min, P = 0.01 and increased FSA 1.92 ± 0.96 to 2.65 ± 1.34 ml (min.100ml), P = 0.03 at the baseline. The association of TRH and TF reduced HR at the baseline from 65 ± 8 to 62 ± 7 bpm (P=0.01) and during exercise with static and dynamic \"handgrip\". HRT alone or associated with TF decreased the HR responses during static and dynamic \"handgrip exercises. In conclusion, the interventions alone or in an associated way promote neural and hemodynamic changes that may contribute to cardiovascular risk reduction in healthy postmenopausal women.

A pós-menopausa é marcada por alterações fisiológicas hemodinâmicas e metabólicas. A terapia de reposição estrogênica é uma forma de amenizar as conseqüências da deficiência hormonal e o exercício físico contribui significativamente para a redução do risco cardiovascular. O objetivo desse estudo foi avaliar em mulheres pós-menopausadas os efeitos isolados e associados da terapia oral estrogênica (TRH) e do treinamento físico aeróbio (TF) nas respostas hemodinâmicas e neurais basais e durante os exercícios com handgrip. Quarenta e cinco mulheres (51±3 anos), histerectomizadas, com e sem ovários, saudáveis, realizaram uma sessão experimental e, posteriormente foram divididas em 4 grupos SED-PLA (n=11), SED-TRH (n=14), TF-PLA (n=12) e TF-TRH (n=8). Os grupos TRH e receberam valerato de estradiol 1mg/dia; PLA receberam placebo; TF, realizaram exercício aeróbio em cicloergômetro por 50 minutos, 3 vezes por semana e SED permaneceram sedentárias. Todas as voluntárias participaram de uma segunda sessão experimental após 6 meses de acompanhamento. Nas sessões experimentais foram avaliadas a atividade nervosa simpática periférica (ANSP - microneurografia), pressão arterial, freqüência cardíaca (FC - método oscilométrico Dixtal no membro inferior), fluxo sangüíneo do antebraço (FSA - pletismografia) em um período basal e durante exercícios estático e dinâmico com handgrip a 30% da força de contração máxima. Para análise estatística foi utilizada ANOVA. O TF isoladamente diminuiu ANSP de 40±7 a 34±4 impulsos/min, (P=0,01) e aumentou FSA de 1,92±0,96 a 2,65±1,34 ml(min.100ml), P=0,03 no período basal. TRH e TF associados reduziram a FC no período basal de 65±8 para 62±7 bpm (P=0,01) e durante o exercício estático e dinâmico com handgrip. A TRH de maneira isolada ou associada ao TF diminuiu as respostas de FC durante os exercícios estático e dinâmico com handgrip. Em conclusão, as intervenções de maneira isolada ou associada promovem alterações hemodinâmicas e neurais que podem contribuir para redução do risco cardiovascular de mulheres pós-menopausadas saudáveis. / The post-menopause is marked by physiological hemodynamic and metabolic changes. The estrogen replacement therapy is a way to reduce the consequences of hormone deficiency and physical exercise contributes significantly to the reduction of cardiovascular risk. The aim of this study was to evaluate in post-menopausal women the isolated and associated effects of oral estrogen therapy (TRH) and physical training (TF) in the neural and hemodynamic responses during baseline and \"handgrip\" exercises. Forty-five women (51 ± 3 years), hysterectomized, with or without ovaries, healthy, participated of an initial session and then they were divided into 4 groups SEDPLA (n = 11), SED-TRH (n = 14), TF-PLA (n = 12) and TF-TRH (n = 8). The TRH groups received estradiol valerate 1 mg / day; PLA placebo; TF, performed aerobic exercise on a cycle ergometer for 50 minutes, 3 times a week and SED remained sedentary. All subjects participated in a second experimental session after 6 months of follow-up. In the experimental sessions peripheral sympathetic nerve activity (ANSP - microneurography), blood pressure, heart rate (FC - oscillometry - Dixtal lower limb), forearm blood flow (FSA - plethysmography) were evaluated at the baseline period and during static and dynamic \"handgrip\" exercises at 30% of the maximum force. ANOVA was used for the statistica analysis. The TF alone decreased ANSP from 40 ± 7 to 34 ± 4 bursts/min, P = 0.01 and increased FSA 1.92 ± 0.96 to 2.65 ± 1.34 ml (min.100ml), P = 0.03 at the baseline. The association of TRH and TF reduced HR at the baseline from 65 ± 8 to 62 ± 7 bpm (P=0.01) and during exercise with static and dynamic \"handgrip\". HRT alone or associated with TF decreased the HR responses during static and dynamic \"handgrip exercises. In conclusion, the interventions alone or in an associated way promote neural and hemodynamic changes that may contribute to cardiovascular risk reduction in healthy postmenopausal women.

As maiores taxas de incidência de câncer de mama ocorrem em mulheres idosas, que apresentam tumores com expressão de receptores de estrógeno e/ou progesterona, de baixo estadiamento e menor taxa de proliferação, se comparado com as jovens. Um dos fatores de predisposição ao câncer de mama é mutação germinativa nos genes BRCA1 ou BRCA2, que podem compreender entre 5-10% das pacientes diagnosticadas. A grande maioria dos casos são ditos esporádicos, em que não há como estabelecer um único fator determinante. Dentre o escopo de possíveis causas estão as mutações somáticas, acumuladas no tecido mamário ao longo da vida. A identificação destas mutações permite melhor compreensão da carcinogênese e possibilita a criação de tratamentos cada vez mais personalizados. O gene PIK3CA, por exemplo, já está determinado como driver (responsáveis pela obtenção de vantagem seletiva de um determinado clone) para câncer de mama. As mutações patogênicas que ocorrem neste gene levam a ativação da via de Akt/mTOR, entre outras, que mantém o ciclo celular ativo. Um gene que vem sendo estudado recentemente é o PRKD1, cujas funções parecem estar ligadas à manutenção do fenótipo epitelial das células do tecido mamário. Assim, o objetivo desse trabalho identificar mutações germinativas nos genes BRCA1 e BRCA2, analisando também o histórico familiar para câncer de mama/ovário/próstata, e mutações somáticas no gene PRKD1 em pacientes pós menopausadas,. Foram incluídas quarenta e nove pacientes diagnosticadas com carcinoma ductal invasivo em idade superior a 54 anos, que preenchessem critérios da NCCN (National Comprehensive Cancer Network) para Síndrome de Câncer de Mama e/ou Ovário Hereditário e tinham disponível um fragmento tumoral emblocado em parafina coletado na ausência de tratamento neo adjuvante. A extração de DNA foi realizada a partir do sangue periférico para sequenciamento de BRCA1 e BRCA2, realizado através da plataforma Ion Torrent(TM) ou pelo método de Sanger. Os resultados obtidos por Ion Torrent(TM) foram analisados, primeiramente, através da ferramenta online Ion Reporter e os de Sanger através do programa Mutation Surveyor v.3.20. Para a caractetização das variantes encontradas foram utilizados: os bancos de dados BIC, LOVD, LOVD-IARC, UMD e ClinVar além dos preditores in silico da conservação dos aminoácidos entre as espécies Polyphen-2, SIF, Provean e AlignGVGD e do preditor de efeito no splicing HSF e bancos de dados de frequência alélica ExAC, 1000 genomas e NHLBI GO Exome Sequencing Project, seguindo os critérios da American College of Medical Genetics and Genomics em conjunto com a Association for Molecular Pathology. Para caracterização de mutação somática do gene PRKD1 determinou-se duas regiões de maior importância para serem sequenciadas: Ser738/Ser742 e Ser910 que fosforilam o domínio quinase da proteína, ativando-o. Vinte e três amostras tumorais tiveram DNA extraído. Também foi realizada uma análise das informações sobre PRKD1 do banco de dados COSMIC (Catalogue of Somatic Mutations in Cancer) e a construção de curvas de sobrevida (Kaplan-Meier) da expressão de PRKD1 utilizando a ferramenta online KM Plotter. A idade mediana das pacientes foi de 62 anos ao diagnóstico e de 64 anos na época de inclusão no estudo. A maioria tinha tumores de grau histológico II (63,27%), estádio clinico II (20%) e do subtipo luminal B (53,06%). Trinta e duas relataram parentes de primeiro grau afetados com câncer de mama/ovário/ próstata. Trinta e oito pacientes tiveram sequenciamento completo de BRCA1 e BRCA2 por Ion Torrent(TM) e onze tiveram sequenciamento parcial de BRCA1 e BRCA2 por Sanger. Variantes patogênicas foram encontradas em quatro pacientes (BRCA1=2/BRCA2=2). Uma nova variante missense foi identificada em BRCA2: c.3371A > G (p.Q1124R). Para o sequenciamento de PRKD1 quinze foram sequenciadas para Ser910 e de oito foi possível analisar o resultado. Nenhuma variante patogênica foi encontrada. Os dados obtidos sobre PRKD1 no COSMIC foram: de 2773 amostras, em apenas 15 (0,54%) foram identificadas mutações em PRKD1, 46% (7/15) provém de mulheres com idade superior a 55 anos e subtipo molecular Luminal. PRKD1 apresenta maiores frequência de mutação em câncer de intestino grosso (4,22%) e pele (4,02%). As curvas de sobrevida construídas no KM Plotter demonstram a alta expressão do gene parece ter impacto positivo na sobrevida das pacientes. Apesar da baixa frequência de mutações no PRKD1 este gene, outros dados demonstram que parece ter um papel de gene supressor de tumor no câncer de mama, que deve ser inibido de através de outros mecanismos como metilaçao de DNA / The highest rates of breast cancer incidence occur in elderly women, who present estrogen and / or progesterone receptor tumors, with a low clinical staging and lower proliferation rate compared to the young women. One of the factors predisposing to breast cancer is germline mutation in the BRCA1 or BRCA2 genes, which may comprise between 5-10% of the diagnosed patients. The vast majority of cases are said to be sporadic, in which there is no way to establish a single determining factor. Among the scope of possible causes are somatic mutations, accumulated in the breast tissue throughout life. The identification of these mutations allows a better understanding of carcinogenesis and enables the creation of increasingly personalized treatments. The PIK3CA gene, for example, is already determined as a driver (responsible for the selective advantage of a particular clone) for breast cancer. The pathogenic mutations that occur in this gene lead to the activation of Akt / mTOR pathway, among others, which keeps the cell cycle active. One gene that has recently been studied is PRKD1, whose functions seem to be linked to the maintenance of the epithelial phenotype of the mammary tissue cells. Thus, the objective of this work was to identify germline mutations in BRCA1 and BRCA2 genes, also analyzing the family history for breast / ovarian / prostate cancer, and somatic mutations in the PRKD1 gene in postmenopausal patients. Forty-nine patients diagnosed with ipsilateral ductal carcinomas over the age of 54 years who completed NCCN (National Comprehensive Cancer Network) criteria for Breast Cancer and / or Hereditary Ovarian Syndrome and had a tumor paraffin embedded in paraffin collected in the absence of neo adjuvant treatment available. DNA extraction was performed from the peripheral blood for sequencing of BRCA1 and BRCA2, performed through the Ion Torrent (TM) platform or by the Sanger method. The results obtained by Ion Torrent (TM) were first analyzed through the online tool Ion Reporter and those by Sanger through the program Mutation Surveyor v.3.20. The BIC, LOVD, LOVD-IARC, UMD and ClinVar databases were used in addition to the in silico predictors of amino acid conservation among Polyphen-2, SIF, Provean and AlignGVGD species and the effect predictor in the HSF splicing and allelic frequency databases ExAC, 1000 genomes and the NHLBI GO Exome Sequencing Project, following the criteria of the American College of Medical Genetics and Genomics in conjunction with the Association for Molecular Pathology. In order to characterize the somatic mutation of the PRKD1 gene, we determined two regions of greater importance to be sequenced: Ser738 / Ser742 and Ser910 that phosphorylate the protein kinase domain, activating it. Twenty-three tumor samples had DNA extracted. An analysis of PRKD1 information from the COSMIC (Catalog of Somatic Mutations in Cancer) database and the construction of survival curves (Kaplan-Meier) for PRKD1 expression using the online KM Plotter tool was also performed. The median age of the patients was 62 years at diagnosis and 64 years at the time of inclusion in the study. Most of them had tumors of histological grade II (63.27%), clinical stage II (20%) and molecular subtype luminal B (53.06%). Thirty-two reported first-degree relatives affected with breast / ovarian / prostate cancer. Thirty-eight patients had BRCA1 and BRCA2 complete sequencing by Ion Torrent (TM) and eleven had BRCA1 and BRCA2 partial sequencing by Sanger. Pathogenic variants were found in four patients (BRCA1 = 2 / BRCA2 = 2). For PRKD1 sequencing, fifteen patients tumors were sequenced for Ser910 and in eight samples it was possible to analyze the result. No pathogenic variant was found. The data obtained on PRKD1 in COSMIC were: from 2773 samples, in only 15 (0.54%) mutations were identified in PRKD1, 46% (7/15) came from women aged over 55 years and had tumor molecular subtype Luminal. PRKD1 shows higher mutation frequency in cancer of the large intestine (4.22%) and skin (4.02%). The survival curves constructed in KM Plotter demonstrate the high expression of the gene seems to have a positive impact on the patients survival . Despite the low frequency of mutations in PRKD1 gene, other data demonstrate that it appears to play a role of tumor suppressor gene in breast cancer, which must be inhibited by other mechanisms such as DNA methylation

<p>Funkcija nosa povezana je sa različitim anatomskim, fiziolo&scaron;kim i emocionalnim faktorima. Postoji mnogo teorija koje su poku&scaron;ale da objasne efekat ženskih polnih hormona (estrogena i progesterona) na fiziologiju nosa, ali sam mehanizam njihovog dejstva jo&scaron; uvek ostaje izazov za mnoge istraživače. Prethodno je opisano da ženski polni hormoni mogu da izazovu nazalnu opstrukciju, povećavajući ekspresiju histaminskih H1 receptora i menjajući koncentraciju neurotransmitera, &scaron;to dovodi do edema nosne sluznice i modifikacije nazalnog otpora. Kada je reč o mirisnoj funkciji na malom broju ispitanika i u različito dizajniranim studijama je pokazano da je u fazi ovulacije mirisni prag značajno niži u odnosu na folikularnu i luteinsku fazu, međutim ne postoje podaci o identifikaciji i diskriminaciji mirisa u menstrualnom ciklusu. Nizak nivo estrogena prouzrokovan fiziolo&scaron;kom atrofijom jajnika u postmenopauzi može dovesti do hiposmije ili čak anosmije, &scaron;to predstavlja jo&scaron; jedan dokaz o osetljivosti nazalne sluznice na estrogen.&nbsp; Cilj ovog istraživanja je bio da se ispita uticaj ženskih polnih hormona na respiratornu i mirisnu funkciju nosa u menstrualnom ciklusu i postmenopauzi. Istraživanje je u celosti prospektivno, sprovedeno je na Zavodu za fiziologiju, Medicinskog fakulteta, Univerziteta u Novom Sadu. Uključeno je 204 osoba ženskog pola koje su bile podeljene u dve grupe. Prvu grupu su činile 103 devojke uzrasta 23,126 &plusmn; 4,597 godina u reproduktivnom periodu sa regularnim menstrualnim ciklusom i 101 žena prosečnog uzrasta 60,069 &plusmn; 5,570 u postmenopauzi. Respiratorna i mirisna funkcija nosa procenjene su uz pomoć odgovarajućih standaradizovanih objektivnih i subjektivnih metoda. Funkcija donjih disajnih puteva ispitana je uz pomoć spirometrije. Kod žena u reproduktivnom periodu testiranje se vr&scaron;ilo u fazi ovulacije i lutealnoj fazi menstrualnog ciklusa, a kod ispitanica u postmenopauzi jednom. Nakon određivanja prvog plodnog dana ispitanice su uz pomoć standardizovanih urin - tračica za određivanje pika luteinizirajućeg hormona u urinu utvrđivale momenat ovulacije, dok se drugo testiranje u lutealnoj fazi vr&scaron;ilo sedam dana nakon prvog. Respiratorna funkcija nosa je značajno lo&scaron;ija u fazi ovulacije u odnosu na progesteronsku fazu menstrualnog ciklusa,ali se značajno ne razlikuje između žena u reproduktivnom periodu i žena u postmenopauzi. Subjektivni osećaj nazalne opstrukcije značajno se ne razlikuje u različitim fazama menstrualnog ciklusa, kao ni između testiranih populacija zdravih žena. Sposobnost identifikacije mirisa je statistički značajno slabija, a subjektivni osećaj intenziteta mirisa izraženiji u fazi ovulacije u odnosu na luteinsku fazu menstrualnog ciklusa. Međutim, sposobnost identifikacije mirisa značajno je lo&scaron;ija kod žena u postmenopauzi u odnosu na obe faze menstrualnog ciklusa. Reaktivnost nosne sluznice značajno je veća u fazi ovulacije u odnosu na lutealnu fazu menstrualnog ciklusa, ali se ista ne razlikuje između žena u reproduktivnom period i žena u postmenopauzi. Respiratorna i mirisna funkcije nosa u testiranim populacijama zdravih žena nisu značajno povezane.</p> / <p>The nasal function is associated with various anatomical, physiological and emotional factors. There are many theories that have tried to explain the effect of female sex hormones (estrogen and progesterone) on the nasal physiology, but the mechanism still remains unknown for many researchers. It has been previously described that female sex hormones can cause nasal obstruction by increasing the expression of histamine H1 receptors and altering the concentration of neurotransmitters, which leads to edema of the nasal mucosa and modification of nasal resistance. When it comes to olfaction on a small number of subjects and in differently designed studies, it was shown that in the ovulatory phase the olfactory threshold is significantly lower compared to the follicular and luteal phase, however there are no data on the identification and discrimination of odors in the menstrual cycle. Low estrogen levels caused by physiological atrophy of the ovaries in postmenopause can lead to hyposmia or even anosmia, which is another proof of the sensitivity of the nasal mucosa to estrogen.&nbsp; The aim of this study was to examine the effect of female sex hormones on respiratory and olfactory function of the nose in the menstrual cycle and postmenopause. The research is prospective and it was conducted at the Department of Physiology, Faculty of Medicine, University of Novi Sad. It included 204 females who were divided into two groups. The first group consisted of 103 women aged 23.126 &plusmn; 4.597 years in the reproductive period with a regular menstrual cycle and 101 women with an average age of 60.069 &plusmn; 5.570 in the postmenopausal period. The respiratory and olfactory function of the nose were assessed using appropriate standardized objective and subjective methods. The lower airway function was examined using spirometry. Young women in reproductive period were tested twice, in the ovulatory and luteal phase of the menstrual cycle, and the postmenopausal women were tested only once. After menstrual bleeding the participans used standardized urine strips consecutively day by day to determine ovulation (the peak of the luteinizing hormone (LH) in plasma which pointed out the estrogen plasma peak). The test was positive if two horizontal pink streaks appeared on the strip 5 to 10 minutes after the contact with the urine. One pink streak indicates a correctly performed test, while the second streak appears only if there is an LH peak. Within 24 hours of confirmed LH peak, the subjects were tested for the first time. The second measurement was performed in the luteal phase of the menstrual cycle (the progesterone plasma peak) seven days after the first one.&nbsp; The nasal respiratory function is significantly worse in the ovulatory phase compared to the luteal phase of the menstrual cycle, but it does not differ significantly between women in the reproductive period and postmenopausal women. The subjective sense of the nasal obstruction does not differ significantly in different phases of the menstrual cycle, as well as between tested populations of healthy women. The odor identification ability is statistically significant weaker and the subjective sense of odor intensity is more pronounced in the ovulatory phase compared to the luteal phase of the menstrual cycle. However, the ability to identify odors is significantly worse in postmenopausal women compared to both phases of the menstrual cycle. The reactivity of the nasal mucosa is significantly higher in the ovulatory phase compared to the luteal phase of the menstrual cycle, but it does not differ between women in the reproductive period and postmenopausal women. The respiratory and olfactory nasal functions in these tested populations are not significantly corelated.</p>

Introduction: The late menopausal transition is a time of increased risk of depression in the general population. Nonetheless, mood course during the late menopausal transition in women with bipolar disorder in relatively unknown. Methods: Mood state data in 519 reproductive age women (5989 clinic visits), 116 late menopausal transition (perimenopausal) women (2046 visits), and 133 postmenopausal women (1,437 visits) with bipolar disorder who were receiving optimized naturalistic treatment in the multisite STEP-BD study over an average of 19.8±15.5 months were analyzed for proportion of clinic visits with syndromal depression, mood elevation and euthymia between the three groups. History of postpartum and perimenstrual mood exacerbation as well as hormone therapy use were evaluated as potential predictors of mood. Results: No significant difference in the proportion of clinic visits with syndromal depression was found between reproductive age (18.1%), perimenopausal (18.1%) and postmenopausal (19.3%) women. Reproductive age women had significantly greater proportion of visits with syndromal mood elevation (5.3%) compared to perimenopausal (4.1%, Z=2.1, p2(3, N = 9960) = 19.8, p Conclusions: While proportion of clinic visits with syndromal depression did not differ among the three reproductive groups, thirteen women who had recorded transition from perimenopause to postmenopause showed significantly greater depression than reproductive age, perimenopausal or postmenopausal women. Proportion of visits with euthymia or with syndromal mood elevation decreased from reproductive age to perimenopausal to postmenopausal women. Reported history of mood exacerbation during times of hormonal fluctuation, or current use of hormone therapy, was not significantly associated with depression during the perimenopause. Limitations include women excluded due to absence of menstrual data. Future studies should include hormonal assessments.

Background: Recent studies are changing the way physicians and patients view hormone replacement therapy (HRT). This study was performed at the East Tennessee State University (ETSU) internal medicine clinic to evaluate the current behaviors of university physicians and patients with respect to HRT. Methods: A retrospective chart review was conducted at the main internal medicine outpatient clinic at ETSU. Two hundred seventy-four postmenopausal female patients were randomly selected using a computerized systematic sampling technique of International Classification of Diseases, Ninth Revision (ICD-9) codes for menopause or postmenopause. The study period was from July 2002 until June 2004. Patients were postmenopausal women age 35 years or over who had been seen by their physicians at least twice a year during the study period. Patients who were noncompliant with HRT or physician's visits or had contraindications or side effects to HRT mandating discontinuation of the treatment were excluded. Data regarding physicians' patterns in discussion and discontinuation of the therapy and patients' responses were collected. Epi Info 2002 was used for statistical analysis. Results: One hundred seventy-seven patients met all of the criteria, of whom 140 were 35 to 75 years of age. Of this age group, 49 patients (35%) had coronary artery disease (CAD), 101 (72.1%) were on HRT prior to July 2002, and 30 (21.4%) had osteoporosis. Seventy-five patients (53.6%) had documented discussions with their physicians about HRT after July 2002. Most patients who were on HRT had no CAD (p = .0008). Of the patients who were on HRT, only 36 (35.6%) continued treatments (23 continued the same dose, and 13 had the dose modified), whereas 65 (64.3%) had treatments discontinued. HRT discussions were carried on mostly when patients had treatments stopped or modified (p = .0032). Of these patients who had discussions, 60 (80%) were advised to stop or modify the dose and agreed, and only 15 (20%) disagreed or received unbiased discussions from their physicians about HRT. Thiry-seven patients were over 75 years of age. This older group had a higher rate of HRT discontinuation (82%) but a lower rate of documented discussion (22%) than the younger group. Conclusion: Physicians should pay more attention to the importance of providing high-quality and well-balanced patient counseling when addressing uncertain treatments and adequately document discussions with patients in medical records.

Pacientes com câncer de mama apresentam menores níveis de 1,25(OH)2D3 ou 25(OH)D3 em relação às mulheres sem a doença. Embora linhagens de câncer de mama apresentem inibição do crescimento em concentrações supra-fisiológicas de 1,25(OH)2D3, forma ativa da vitamina D, ainda não se demonstrou se o hormônio exerce efeito antiproliferativo, em concentrações fisiológicas, em tumores de seres humanos. A suplementação de calcitriol pode ser indica a mulheres pós-menopausadas para prevenir a perda óssea. Nosso objetivo foi avaliar em pacientes com câncer de mama, pós menopausadas, a dimensão do tumor, taxa de proliferação (expressão de Ki67), concentração sérica de 1,25(OH)2D3 e 25(OH)D3, expressão gênica tumoral do receptor de vitamina D (VDR) e alguns genes alvos como, CYP24A1, CYP27B1, IGFBP3, PHB, TGFB2, CDKN1A, CDKN1B, CYP27B1, MYC, CAMP, TXNRD2, antes a após um mês de suplementação oral de calcitriol. Foram estudadas 24 pacientes com doença operável, idade mediana de 57 anos. As primeiras 10 pacientes e as 14 seguintes receberam 0,25 e 0,50g/dia de calcitriol, respectivamente, por um período mediano de 31 dias. Três quartos das pacientes apresentavam nível sérico de insuficiência de 25(OH)D3 ou insuficiência relativa (<30ng/ml) e após a suplementação, nenhuma paciente apresentou elevação dos níveis séricos de 1,25(OH)2D3 e 25(OH)D3. Embora a dimensão tumoral, mensurada por ultrasonografia, não apresentasse variação, a imuno-expressão de Ki67 sofreu um redução relativa mediana de 40%. A expressão relativa de VDR, CYP24A1, CYP27B1, IGFBP3, PHB, TGFB2, CDKN1A, CDKN1B, CYP27B1, MYC, CAMP, TXNRD2 não se alterou com a suplementação. Nossos dados indicam que tumores de mama expressam VDR, e que após suplementação oral de calcitriol, ocorre uma redução da proliferação. Este efeito merece ser elucidado, desde que genes alvo clássicos da 1,25(OH)2D3 não parecem ser mediadores do efeito anti-proliferativo, em amostras de câncer de mama de pacientes pós menopausadas. / Breast cancer patients present lower 1,25(OH)2D3 or 25(OH)D3 serum levels than unaffected women. Although breast cancer cell lines are growth inhibited by vitamin D supra-physiological concentrations, there is much uncertainty about the anti-proliferative effect of physiological concentrations of 1,25(OH)2D3, the active form of vitamin D, in breast cancer specimens in vivo. Vitamin D supplementation to post-menopausal women may be indicated to reduce bone loss. Our aim was to evaluate tumor dimension, proliferation rate (Ki67 expression), 25(OH)D3 and 1,25(OH)2D3 serum concentration, and tumor expression of vitamin D receptor (VDR), and of some target genes as CYP24A1, CYP27B1, IGFBP3, PHB, TGFB2, CDKN1A, CDKN1B, CYP27B1, MYC, CAMP, TXNRD2, before and after a one month calcitriol supplementation to post-menopausal breast cancer patients. Twenty four patients with operable disease, median age 57 years, were enrolled. The first tem patients were supplemented with calcitriol 0.25g/d and the next 14 patients, with 0.50g/d, for a median period of 31 days. Three fourths of the patients presented 25(OH)D3 insufficiency or relative insufficiency (<30 ng/mL) and after calcitriol supplementation, none of them presented an elevation of 1,25(OH)2D3 or 25(OH)D3 serum concentration. Although tumor dimension, evaluated by ultrasonography, did not vary, a median relative reduction of 40% in Ki67 immuno-expression, was observed. No differences in VDR, CYP24A1, CYP27B1, IGFBP3, PHB, TGFB2, CDKN1A, CDKN1B, CYP27B1, MYC, CAMP, TXNRD2 mRNA relative expression were detected between pre and post-supplementation samples. No differences in VDR, CYP27B1 and CYP24A1 tumor relative expression were detected following supplementation. Our data indicate that VDR expression is detected in breast cancer samples and that growth inhibition takes place after calcitriol oral supplementation. This anti-proliferative effect deserves further investigation, as classical target genes do not seem to be involved.

<p>UVOD: Artroza &scaron;aka predstavlja jednu od najče&scaron;ćih mi&scaron;ićno-skeletnih bolesti. Manifestuje se bolom, nekada otokom, deformacijom i gubitkom funkcije &scaron;aka. Postoje različita mi&scaron;ljenja o povezanosti osteoartroze (OA) i osteoporoze (OP) kao dva najče&scaron;a skeletna poremećaja. CILJ: istraživanja je da se utvrde faktori rizika za nastanak OA &scaron;aka, uporedi mineralna ko&scaron;tana gustina kod pacijenata sa OA &scaron;aka sa kontrolnom grupom i utvrdi značaj metaboličkog sindroma kod pacijenata sa OA &scaron;aka. MATERIJAL I METODE: Istraživanje je obavljeno u periodu od jedne godine kod bolesnika sa OA &scaron;aka &ndash; eksperimentalna grupa, i u kontrolnoj grupi bez OA. OA &scaron;aka je definisana na osnovu bola, klinički prisutnih deformiteta &scaron;aka kod žena u postmenopauzi starosne dobi od 60-70 godina i radiografskih promena ( drugog do četvrtog stepena prema Kellgren-Lowrencovoj skali). Analizirani su faktori rizika odgovorni za nastanak OA &scaron;aka, povezanost OA &scaron;aka sa snagom stiska &scaron;ake, mineralnom ko&scaron;tanom gustinom i metaboličkim sindromom. Analazirirana je i funkcija &scaron;ake pomoću tri validirana upitnika: Michigan Hand Outcomes Questionnaire (MHQ, Duruoz Hand Indeks (DHI), Health Assessment Questionnaire (PROMIS HAQ). Statistička obrada podataka rađena je u programu SPSS verzija 25. REZULTATI: Prosečna starost pacijentkinja je bila 65,89&plusmn;3,67 godina. Eksperimentalna i kontrola grupa se statistički razlikuju prema porodičnoj anamnezi o strukturnim promenama zglobova &scaron;aka, prema bolnosti &scaron;aka u miru, bolnosti &scaron;aka pri palpaciji, uzdržavanju od pokreta prstiju &scaron;aka, snage stiska &scaron;ake, metaboličkom sindromu( p&lt;0,001). Kao značajni prediktori za nastanak osteoartroze &scaron;aka su se izdvojili pozitivna porodična anamneza o strukturnim promenama za zglobovima &scaron;aka i metabolički sindrom ( p&lt;0,001). Utvrđen je veći broj ispitanica sa normalnom ko&scaron;tanom gustinom u kontrolnoj grupi. Eksperimentalna grupa bolesnica imala je lo&scaron;iju funkciju &scaron;ake, odnosno lo&scaron;iji skor primenom validiranih upitnika ( p &lt;0,001). ZAKLJUČAK: Pacijentkinje sa izraženom osteoartrozom &scaron;aka imaju smanjenu funkciju &scaron;ake, če&scaron;ći metabolički sindrom u odnosu na kontrolnu grupu, ali ne i značajno nižu ko&scaron;tanu gustinu.</p> / <p>INTRODUCTION: Arthritis of the hand is one of the most common musculoskeletal disorders. It manifests as pain, sometimes accompanied by swelling and deformities, which may lead to the loss of hand function. However, there is no consensus on the relationship between osteoarthritis (OA) and osteoporosis (OP) as the two most common skeletal disorders. AIMS: The study aim was to determine the risk factors related to the development of OA in the hand, as well as compare the bone density in patients with hand OA (HOA) with that measured in the control group and establish the significance of metabolic syndrome in the HOA group. MATERIAL AND METHODS: The study was conducted over a 12-month period and included a sample comprising of the experimental (patients affected by HOA) and the control (individuals with no evidence of HOA) group. HOA was diagnosed based on the reported pain, clinical evidence of hand deformities in postmenopausal women aged 60&minus;70, and radiological evidence of physiological changes (Grade II to IV, based on the Kellgren-Lowrence scale). The risk factors for the development of HOA were analyzed, along with the link between HOA and hand grip strength, bone mineral density and metabolic syndrome. Analyses also included had function, as determined by three validated questionnaires: Michigan Hand Outcomes Questionnaire (MHQ), Duruoz Hand Index (DHI), and Health Assessment Questionnaire (PROMIS HAQ). Statistical analyses were performed using the SPSS version 25 computer software. RESULTS: The average age of the sample was 65.89&plusmn;3.67 years. There were statically significant differences between the experimental and the control group with respect to the family history of structural changes in the hand joints, perceived hand pain at rest and when palpated, reluctance to utilize fingers, hand grip strength, and metabolic syndrome (p &lt; 0.001). Family history of structural changes to the hand joints and metabolic syndrome emerged as the strongest predictors of the osteoarthritis of the hand development (p &lt; 0.001). A greater number of the control group members had normal bone mineral density, while the patients assigned to the experimental group had inferior hand function, as determined by the score on the aforementioned validated questionnaires (p &lt; 0.001). CONCLUSION: Postmenopausal women with pronounced osteoarthritis of the hand have reduced hand function, and are more likely to suffer from a metabolic syndrome relative to the control group, while the differences in bone mineral density are not statistically significant.</p>

Για τις Ευρωπαίες γυναίκες ο καρκίνος του σώματος της μήτρας αποτελεί το τέταρτο συχνότερο νεόπλασμα και την δέκατη σε σειρά αιτία θανάτου από καρκίνο. Ανεξάρτητα από το εάν η διακολπική υπερηχογραφία (TVS) αποτελεί δόκιμο μέσο διαλογής (screening) για την ανίχνευση ενδομητρικού καρκίνου σε ασυμπτωματικές μετεμμηνοπαυσιακές γυναίκες, εντούτοις κυριαρχεί στους διαγνωστικούς αλγόριθμους διερεύνησης κάθε μητρορραγίας προς αποκλεισμό του καρκίνου αυτού. Παράλληλα με τα πιθανά οφέλη από την ενσωμάτωση τεχνικών Υπερηχοϋστερογραφίας (SIS) και Doppler στην ενδομητρική απεικόνιση, η δισδιά- στατη “gray scale” διακολπική υπερηχογραφία οφείλει μεγάλο μέρος της προόδου της στην ώθηση από τις εξελίξεις της τεχνολογίας. Μετά την εισαγωγή των διακολπικών ηχοβολέων πολλαπλών συχνοτήτων (multifrequency) και της “αρμονικής” (harmonic) απεικόνισης, τα σύγχρονα υπερηχογραφικά μηχανήματα διαθέτουν επιλογές λογισμι- κού για ενίσχυση της ανάλυσης της αντίθεσης δομών, λεπτών ρυθμίσεων για εξέταση διαφορετικών τύπων ιστών, πολλαπλού εύρους εστίασης, μετάδοσης της δέσμης σε πλάγια διεύθυνση ως προς το ακουστικό παράθυρο, κ.α. Τα παραπάνω, καθώς και φίλτρα μείωσης του θορύβου βελτιστοποιούν την απεικόνιση του ενδομητρίου διευκολύνοντας την αποτίμησή του, ακόμη και στα χέρια άπειρων εξεταστών. Το πάχος της διπλής ενδομητρικής στιβάδας αποτελεί ιστορικά τον πλέον αδιαμφισβήτητο ποσοτικό δείκτη ενδομητρικού καρκίνου, ειδικά στην παρουσία μετεμμηνοπαυσιακής μητρορραγίας. Η συνδυασμένη μελέτη της ενδομητρικής μορφο- λογίας και πάχους παρέχει περισσότερες πληροφορίες, ειδικά στην αποτίμηση της “γκρίζας ζώνης” των 4-10 χιλιοστών ενδομητρικού πάχους, αν και τα ευρήματα των “μορφολογικών” αυτών μελετών δεν υπήρξαν πάντα σταθερά. Με δεδομένη τη σημασία της μορφολογίας στην αποτίμηση του ενδομητρικού ιστού, και αποσκοπώντας στην υπέρβαση του υποκειμενικού χαρακτήρα της ποιοτικής εκτίμησης της υπερηχογραφικής εικόνας, θα ήταν χρήσιμη η εφαρμογή αυτοματοποιημένων τεχνικών που αξιολογούν αντικειμενικά μορφολογικά χαρακτη- ριστικά, όπως η υποβοηθούμενη από υπολογιστή ανάλυση υφής, (“computerized texture analysis”). Στις ψηφιακές εικόνες, η υφή αντικατοπτρίζει τονικές (ένταση των εικονο- στοιχείων) και δομικές (χωρική κατανομή της έντασης των εικονοστοιχείων) ιδιότητες. Η “ανάλυση υφής” αναφέρεται σε αλγόριθμους που ποσοτικοποιούν περιεχόμενο και στοιχεία υφής που πιθανόν, ή όχι, να γίνονται αντιληπτά με το γυμνό μάτι. Δεδομένου ότι στην ιατρική απεικόνιση οι εικόνες περιλαμβάνουν πολλαπλές ιδιότητες των βιολογικών δομών, η ανάλυση υφής των εικόνων αυτών παρέχει ποσοτικές πληροφο- ρίες σχετικές με τα χαρακτηριστικά, τη μορφολογία και τις ιδιότητες των δομών αυτών. Σχήματα ταξινόμησης στηριζόμενα στην υφή έχουν χρησιμοποιηθεί με επιτυχία σε ποικιλία υπερηχογραφικών εφαρμογών. Η βασισμένη σε υπολογιστή αποτίμηση εικόνων του ενδομητρίου έχει βρει κυρίως εφαρμογή στη Υποβοηθούμενη Αναπαραγωγή, αλλά δεν έχει χρησιμοποιηθεί για τη διάγνωση ενδομητρικών κακοηθειών στην δισδιάστατη υπερηχογραφία. Σκοπός της διδακτορικής αυτής διατριβής είναι η αξιολόγηση του εφικτού της υποβοηθούμενης από υπολογιστή ανάλυσης υφής του ενδομητρικού ιστού όπως απεικονίζεται σε δισδιάστατες “gray scale” υπερηχογραφικές εικόνες. Περαιτέρω, διερευνήθηκε το αποτέλεσμα μιας τεχνικής επεξεργασίας βασισμένης σε μετασχη- ματισμό κυματίου (wavelet) στη διαδικασία τμηματοποίησης και χαρακτηρισμού του ενδομητρικού ιστού. / Cancer of the corpus uteri represents the fourth commonest neoplasm among European women and the tenth most common cause of death attributed to cancer. Irrespective whether the use of transvaginal ultrasonography (TVS) as a screening tool for detecting endometrial cancer in asymptomatic postmenopausal women is warranted, TVS dominates most diagnostic algorithms in assessing metrorrhagias to exclude this cancer. Alongside the potential benefits stemming from the integration of Saline Infusion Sonography) and Doppler modalities in endometrial imaging, gray scale TVS showed remarkable advances in the previous decades, largely attributed to the evolution in computer sciences. Following the introduction of multifrequency transvaginal probes and harmonic imaging, modern scanners are equipped with software options that enhance the resolution or the contrast between different structures, fine tune while assessing different types of tissue, implement different depth of focusing, transmit the ultrasonic beam in oblique directions to the acoustic window; all these features, in addition to de-speckle filters optimize the endometrial depiction, facilitating its assessment, even in the hands of moderately skilled operators. Double stripe endometrial thickness has illustrated a remarkable robustness over time as a quantitative indicator of endometrial cancer, especially in the presence of postmenopausal bleeding. The combined consideration of endometrial morphology and thickness has proven particularly beneficial, especially in the assessment of the 4-10 mm endometrial thickness “grey zone”, although the findings of the “morphologic” studies haven’t always been consistent. Given the importance of morphology in assessing endometrial tissue, and aiming to overcome the inherent subjectivity of the qualitative consideration of ultrasonic images, implementation of automated techniques assessing objective morphologic features such as “computerized texture analysis” would be beneficial. In digital images, texture reflects tonal (intensities of image pixels) and structural (spatial distribution of pixel intensities) properties. Texture analysis refers to algorithms that quantify texture content that may, or may not, be visually perceived. Since medical images capture various properties of biological structures, texture analysis of medical images can provide quantitative metrics relevant to structure, morphology and status of biological tissues. Texture based classification schemes have been successfully implemented in a variety of ultrasound applications. Computerized TVS assessment of endometrial morphology, has been applied mainly in assisted reproduction techniques; however, computerized texture analysis has not been implemented for diagnosing endometrial malignancies in grey scale TVS. The aim of this study is to investigate the feasibility of computerized texture analysis in characterizing endometrial tissue as depicted in 2D grey scale TVS images. Furthermore, we assess the effect of a wavelet-based image processing technique in the segmentation and subsequent characterization tasks of endometrial tissue.

Pacientes com câncer de mama apresentam menores níveis de 1,25(OH)2D3 ou 25(OH)D3 em relação às mulheres sem a doença. Embora linhagens de câncer de mama apresentem inibição do crescimento em concentrações supra-fisiológicas de 1,25(OH)2D3, forma ativa da vitamina D, ainda não se demonstrou se o hormônio exerce efeito antiproliferativo, em concentrações fisiológicas, em tumores de seres humanos. A suplementação de calcitriol pode ser indica a mulheres pós-menopausadas para prevenir a perda óssea. Nosso objetivo foi avaliar em pacientes com câncer de mama, pós menopausadas, a dimensão do tumor, taxa de proliferação (expressão de Ki67), concentração sérica de 1,25(OH)2D3 e 25(OH)D3, expressão gênica tumoral do receptor de vitamina D (VDR) e alguns genes alvos como, CYP24A1, CYP27B1, IGFBP3, PHB, TGFB2, CDKN1A, CDKN1B, CYP27B1, MYC, CAMP, TXNRD2, antes a após um mês de suplementação oral de calcitriol. Foram estudadas 24 pacientes com doença operável, idade mediana de 57 anos. As primeiras 10 pacientes e as 14 seguintes receberam 0,25 e 0,50g/dia de calcitriol, respectivamente, por um período mediano de 31 dias. Três quartos das pacientes apresentavam nível sérico de insuficiência de 25(OH)D3 ou insuficiência relativa (<30ng/ml) e após a suplementação, nenhuma paciente apresentou elevação dos níveis séricos de 1,25(OH)2D3 e 25(OH)D3. Embora a dimensão tumoral, mensurada por ultrasonografia, não apresentasse variação, a imuno-expressão de Ki67 sofreu um redução relativa mediana de 40%. A expressão relativa de VDR, CYP24A1, CYP27B1, IGFBP3, PHB, TGFB2, CDKN1A, CDKN1B, CYP27B1, MYC, CAMP, TXNRD2 não se alterou com a suplementação. Nossos dados indicam que tumores de mama expressam VDR, e que após suplementação oral de calcitriol, ocorre uma redução da proliferação. Este efeito merece ser elucidado, desde que genes alvo clássicos da 1,25(OH)2D3 não parecem ser mediadores do efeito anti-proliferativo, em amostras de câncer de mama de pacientes pós menopausadas. / Breast cancer patients present lower 1,25(OH)2D3 or 25(OH)D3 serum levels than unaffected women. Although breast cancer cell lines are growth inhibited by vitamin D supra-physiological concentrations, there is much uncertainty about the anti-proliferative effect of physiological concentrations of 1,25(OH)2D3, the active form of vitamin D, in breast cancer specimens in vivo. Vitamin D supplementation to post-menopausal women may be indicated to reduce bone loss. Our aim was to evaluate tumor dimension, proliferation rate (Ki67 expression), 25(OH)D3 and 1,25(OH)2D3 serum concentration, and tumor expression of vitamin D receptor (VDR), and of some target genes as CYP24A1, CYP27B1, IGFBP3, PHB, TGFB2, CDKN1A, CDKN1B, CYP27B1, MYC, CAMP, TXNRD2, before and after a one month calcitriol supplementation to post-menopausal breast cancer patients. Twenty four patients with operable disease, median age 57 years, were enrolled. The first tem patients were supplemented with calcitriol 0.25g/d and the next 14 patients, with 0.50g/d, for a median period of 31 days. Three fourths of the patients presented 25(OH)D3 insufficiency or relative insufficiency (<30 ng/mL) and after calcitriol supplementation, none of them presented an elevation of 1,25(OH)2D3 or 25(OH)D3 serum concentration. Although tumor dimension, evaluated by ultrasonography, did not vary, a median relative reduction of 40% in Ki67 immuno-expression, was observed. No differences in VDR, CYP24A1, CYP27B1, IGFBP3, PHB, TGFB2, CDKN1A, CDKN1B, CYP27B1, MYC, CAMP, TXNRD2 mRNA relative expression were detected between pre and post-supplementation samples. No differences in VDR, CYP27B1 and CYP24A1 tumor relative expression were detected following supplementation. Our data indicate that VDR expression is detected in breast cancer samples and that growth inhibition takes place after calcitriol oral supplementation. This anti-proliferative effect deserves further investigation, as classical target genes do not seem to be involved.